Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Sarah B Goldberg
Yale University Cancer Center LAO
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
18 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Los Angeles General Medical Center
Los Angeles, California, United States
- Usc / Norris Comprehensive Cancer Center
Los Angeles, California, United States
- Keck Medical Center of Usc Pasadena
Pasadena, California, United States
- University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
- Smilow Cancer Center/yale-New Haven Hospital
New Haven, Connecticut, United States
- Yale University
New Haven, Connecticut, United States
- Moffitt Cancer Center
Tampa, Florida, United States
- Moffitt Cancer Center-International Plaza
Tampa, Florida, United States
- University of Kansas Clinical Research Center
Fairway, Kansas, United States
- University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas, United States
- Nebraska Medicine-Bellevue
Bellevue, Nebraska, United States
- Nebraska Medicine-Village Pointe
Omaha, Nebraska, United States
- University of Nebraska Medical Center
Omaha, Nebraska, United States
- Nyp/columbia University Medical Center/herbert Irving Comprehensive Cancer Center
New York, New York, United States
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
- University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
- University of Pittsburgh Cancer Institute (upci)
Pittsburgh, Pennsylvania, United States
- Huntsman Cancer Institute/university of Utah
Salt Lake City, Utah, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 27 Jun 2018
- Primary completion
- 18 Feb 2025
- Completion
- 1 Jul 2026
- Last update posted
- 26 Jun 2026
- Registered enrollment
- 5
- Registry id
- NCT02971501
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.